- Case report
- Open Access
- Open Peer Review
Urea cycle disorder presenting as bilateral mesial temporal sclerosis – an unusual cause of seizures: a case report and review of the literature
© The Author(s). 2018
- Received: 28 September 2017
- Accepted: 17 June 2018
- Published: 15 July 2018
Urea cycle disorders are secondary to defects in the system converting ammonia into urea, causing accumulation of ammonia and other byproducts which are neurotoxic. Ornithine transcarbamylase deficiency is the most common of the urea cycle disorders and frequently presents with coma or seizures during hyperammonemia. However, seizures can also occur without metabolic decompensation.
We describe a 23-year-old Chinese woman with urea cycle disorder who presented with confusion due to focal seizures arising from the left frontotemporal region. Interestingly, her ammonia levels remained normal during the seizures. Neuroimaging showed bilateral mesial temporal sclerosis. Her seizures were successfully controlled with two anti-epileptic medications.
This case adds evidence of the predisposition of the temporal lobe to injury in urea cycle disorder. Urea cycle disorder can lead to mesial temporal sclerosis which leads to increased susceptibility of patients to seizures regardless of their metabolic state.
- Urea cycle disorder
- Mesial temporal sclerosis
- Magnetic resonance imaging
Urea cycle disorders (UCD) are a group of inborn errors of metabolism caused by the dysfunction of any of the six enzymes or two transport proteins involved in urea biosynthesis. The six enzymes are carbamoyl phosphate synthetase I, N-acetylglutamate synthetase, ornithine transcarbamylase, argininosuccinic acid synthetase, argininosuccinate lyase, and arginase. The two amino acid transport defects are ornithine translocase and aspartate/glutamate carrier. All the UCDs are inherited as autosomal recessive disorders, except for ornithine transcarbamylase (OTC) deficiency. A defect in urea synthesis results in hyperammonemia, which disrupts the aquaporin system and increases astrocyte glutamine synthesis causing brain edema and raised intracranial pressure . The severity of the UCD is influenced by the position of the defective protein in the pathway and the severity of the defect. The clinical presentation is variable with the most severe forms presenting in the neonatal period with seizures, coma, and multiorgan failure. The seizures can be subclinical during acute hyperammonemic episodes. Milder forms of UCD can present at any age with metabolic decompensation or more subtle symptoms such as developmental delay, and behavioral or psychiatric symptoms. However, with good metabolic control of the underlying disease, resultant epilepsy is rare in the course of the disorder .
We describe a patient with UCD who presented with seizures despite having good control of her ammonia levels.
Our patient is a 23-year-old Chinese woman with UCD who presented with seizures 2 years after the latest episode of metabolic decompensation. She was the second child of a non-consanguineous union. Her elder sister and parents were well and there was no history of early deaths in the family, especially male family members. She was delivered at full term via an emergency caesarean section for failure to progress and breech position. Her Apgar was 7 at 1 minute and 8 at 5 minutes, probably due to prolonged maternal anesthesia.
She presented at 14 months of age with gross motor delay and intermittent vomiting after meals. She was alert and interactive. However, she was ataxic and her lower limbs were hypotonic with decreased power and brisk reflexes. The tone, power, and reflexes were normal in her upper limbs. She had intention tremors of the upper limbs. Computed tomography (CT) of her brain did not show any intracranial abnormalities. Her plasma ammonia level was markedly elevated at 327 umol/L (normal range 16 to 53 umol/L). She was treated with intravenously administered sodium benzoate with improvement in the hyperammonemia. She was diagnosed as having OTC deficiency in view of hyperammonemia, elevated glutamine at 1237 umol/L (normal range 400 to 700 umol/L), and elevated urinary orotic acid at 110 mmol/mol creatinine (normal range 0.5 to 3.3 mmol/mol creatinine). Her citrulline level was normal at 17 umol/L (normal range 5 to 60 umol/L). Sequencing of the OTC gene did not detect any pathological variant. The inability to identify a pathological variant by sequencing is not unusual. Pathological point mutation variants are found in approximately 80% of patients with enzymatically confirmed OTC deficiency. The remaining patients either have variants in the regulatory regions, variants within the introns, or have large deletions, all of which would not be detected by the sequencing that was done in this patient.
She presented with the first episode of seizure at 21 years of age. She did not have previous febrile seizures in childhood. There was no family history of epilepsy. She had altered mental state and incoherent speech on presentation. The plasma ammonia levels remained normal, ranging from 16 to 45 umol/L.
Our patient’s neuroimaging finding of bilateral mesial temporal sclerosis was unusual as acquired mesial temporal sclerosis is commonly known to be a consequence of long-standing refractory epilepsy rather than the cause of seizures. She remained seizure free during multiple episodes of hyperammonemia. However, when the clinical seizures occurred, she was not in metabolic decompensation. The temporal relation leads us to postulate that the neuroimaging findings were a result of metabolic abnormalities during her childhood and adolescent years or due to undiagnosed subclinical seizures during metabolic decompensation.
The predilection of the temporal lobes to injury from hyperammonemia is well-described. There is a specific pattern of brain injury in UCDs . Acute hyperammonemia causes reversible changes involving the deep sulci of the insular and perirolandic regions. MRI studies have described hypomyelination, myelination delay, and cystic changes of the white matter and gliosis of the deep gray matter, which occurred months after acute neonatal hyperammonemia as a result of OTC deficiency . Bilateral anterior temporal atrophy and high signal intensity at the temporal cortex have been observed in patients with late onset OTC deficiency, especially in the cingulate gyri and insular cortex . Other MRI findings in OTC deficiency in patients with severe clinical manifestations such as somnolence, seizures, and hemiplegia included extensive infarct-like abnormalities, which were not present in our patient .
Besides routine MRI (T1 and T2 imaging), other neuroimaging modalities have been used to detect earlier measures of brain injury. Routine imaging may only detect damage at the macroscopic level when the patient is symptomatic and may lag behind clinical signs. Diffusion tensor imaging (DTI), which examines the disruption of white matter integrity, functional MRI (fMRI) which maps changes in brain hemodynamics that correspond to cognitive tasks, and proton magnetic resonance spectroscopy (1H MRS) which is able to detect the concentration of neurotoxic byproducts in various areas of the brain  have been used to characterize brain injury in patients with UCDs. In 1H MRS, there is an increase in the glutamine/glutamate signal intensity accompanied by myo-inositol depletion. Other details of these advanced neuroimaging findings are beyond the scope of this case report.
Ammonia is converted to glutamine in astrocytes and being osmotically active, causes cytotoxic edema. It has been postulated by Kurihara et al.  that the T2 abnormalities on MRI may reflect diminished cerebral perfusion and early ischemia.
The neuroimaging findings in other causes of hyperammonemia differ from that due to UCDs. For example, in hepatic encephalopathy, classic MRI abnormalities include high signal intensity in the globus pallidum on T1-weighted images. The pattern of MRI abnormalities may thus also be able to guide the clinician in the workup for hyperammonemia .
With the knowledge of the specific neuroimaging findings of our patient, we are able to better determine the etiology and prognosis of focal epilepsy. She will probably need long-term anti-epileptic medications for seizure control.
To the best of our knowledge, the finding of bilateral mesial temporal sclerosis adds further evidence of the susceptibility of temporal lobes to injury from hyperammonemia. UCD can lead to mesial temporal sclerosis which leads to increased susceptibility of patients to seizures regardless of their metabolic state. This case also highlights the importance of neuroimaging in the workup of seizures in patients with UCD without metabolic decompensation.
Availability of data and materials
The dataset supporting the conclusions of this article is included within the article.
Acquisition of data – FW, DG, and HO. Analysis and interpretation of data – FW, DG, and HO. Drafting of the manuscript – FW. Critical revision of manuscript – DG and HO. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The authors declare that ethics approval was not required for this case report.
Consent for publication
Written informed consent was obtained from the patient’s parent for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Machado MC, Pinheiro da Silva F. Hyperammonemia due to urea cycle disorders: a potentially fatal condition in the intensive care setting. J Intens Care. 2014;2:22.View ArticleGoogle Scholar
- Wolf NI, Bast T, Surtees R. Epilepsy in inborn errors of metabolism. Epileptic Disord. 2005;7(2):67–81.PubMedGoogle Scholar
- Gropman AL. Patterns of brain injury in inborn errors of metabolism. Semin Pediatr Neurol. 2012;19(4):203–10.View ArticlePubMedPubMed CentralGoogle Scholar
- Gropman AL. Brain imaging in urea cycle disorders. Mol Genet Metab. 2010;100(Suppl 1):S20–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Kurihara A, Takanashi J, Tomita M, Kobayashi K, Ogawa A, Kanazawa M, et al. Magnetic resonance imaging in late-onset ornithine transcarbamylase deficiency. Brain and Development. 2003;25:40–4.View ArticlePubMedGoogle Scholar
- Mamourian AC, du Plessis A. Urea cycle defect: a case with MR and CT findings resembling infarct. Pediatr Radiol. 1991;21:594–5.View ArticlePubMedGoogle Scholar
- Gropman AL. Expanding the diagnostic and research toolbox for inborn errors of metabolism: the role of magnetic resonance spectroscopy. Mol Genet Metab. 2005;86:2–9.PubMedGoogle Scholar
- Rovira A, Alonso J, Cordoba J. MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol. 2008;29(9):1612–21.View ArticlePubMedGoogle Scholar